- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 4
The Center for Biosimilars® recaps the top news for the week of February 4, 2019.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 4.
Number 5: Fresenius Kabi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for its biosimilar adalimumab.
Number 4: In a recent paper, Italian rheumatology providers called into question whether newly published results from the DANBIO registry can be used to guide non-medical switching.
Number 3: Researchers have provided detailed results from the phase 3 REFLECTIONS trial that found Pfizer's trastuzumab biosimilar to be equivalent to the EU reference.
Number 2: A recent white paper found that the assumption that Medicare Part B payment rates lead providers choose costlier treatments in order to benefit from larger add-on payments is incorrect.
Number 1: Mundipharma announced that it has launched Pelmeg, a biosimilar pegfilgrastim, in Germany, the Netherlands, and Ireland.
Finally, last week, our e-newsletter asked if drug makers should be required to disclose their research and development costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
